Live Biotherapeutic Products and Probiotics for the Skin
The skin microbiome is essential for the proper barrier functions of the skin, preventing the invasion of pathogens and regulating immune responses. When disrupted, recurrent conditions including atopic dermatitis, acne, or chronic wounds can result. Live biotherapeutic products (LBPs), an emerging...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley-VCH
2021-12-01
|
| Series: | Advanced NanoBiomed Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/anbr.202100118 |
| _version_ | 1827944449193279488 |
|---|---|
| author | Ava M. Vargason Aaron C. Anselmo |
| author_facet | Ava M. Vargason Aaron C. Anselmo |
| author_sort | Ava M. Vargason |
| collection | DOAJ |
| description | The skin microbiome is essential for the proper barrier functions of the skin, preventing the invasion of pathogens and regulating immune responses. When disrupted, recurrent conditions including atopic dermatitis, acne, or chronic wounds can result. Live biotherapeutic products (LBPs), an emerging class of therapeutics based on live bacteria, are promising for treating these challenging conditions. Several topical LBPs have entered clinical trials for the skin and are quickly reporting positive data from early trials. Herein, a selection of these clinical trials are analyzed to highlight the potential of topical LBPs and provide insights into their identification and development. In addition, the outstanding challenges that need to be addressed for the full translation of these LBPs into clinical therapeutics are commented. In doing so, an overview of the existing formulation landscape for microbial‐based topical products, including direct‐to‐consumer probiotics, is provided. Once the outstanding formulation and delivery challenges are addressed for LBPs and the first topical LBPs reach the market, they will be a promising modality that provides novel therapeutic mechanisms for addressing previously difficult‐to‐treat conditions. |
| first_indexed | 2024-03-13T10:29:27Z |
| format | Article |
| id | doaj.art-e8eaf427887e42df9a322d080ecd144c |
| institution | Directory Open Access Journal |
| issn | 2699-9307 |
| language | English |
| last_indexed | 2024-03-13T10:29:27Z |
| publishDate | 2021-12-01 |
| publisher | Wiley-VCH |
| record_format | Article |
| series | Advanced NanoBiomed Research |
| spelling | doaj.art-e8eaf427887e42df9a322d080ecd144c2023-05-19T03:06:28ZengWiley-VCHAdvanced NanoBiomed Research2699-93072021-12-01112n/an/a10.1002/anbr.202100118Live Biotherapeutic Products and Probiotics for the SkinAva M. Vargason0Aaron C. Anselmo1Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC 27599 USADivision of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC 27599 USAThe skin microbiome is essential for the proper barrier functions of the skin, preventing the invasion of pathogens and regulating immune responses. When disrupted, recurrent conditions including atopic dermatitis, acne, or chronic wounds can result. Live biotherapeutic products (LBPs), an emerging class of therapeutics based on live bacteria, are promising for treating these challenging conditions. Several topical LBPs have entered clinical trials for the skin and are quickly reporting positive data from early trials. Herein, a selection of these clinical trials are analyzed to highlight the potential of topical LBPs and provide insights into their identification and development. In addition, the outstanding challenges that need to be addressed for the full translation of these LBPs into clinical therapeutics are commented. In doing so, an overview of the existing formulation landscape for microbial‐based topical products, including direct‐to‐consumer probiotics, is provided. Once the outstanding formulation and delivery challenges are addressed for LBPs and the first topical LBPs reach the market, they will be a promising modality that provides novel therapeutic mechanisms for addressing previously difficult‐to‐treat conditions.https://doi.org/10.1002/anbr.202100118live biotherapeutic productsprobioticsskin formulationskin microbiometopical delivery |
| spellingShingle | Ava M. Vargason Aaron C. Anselmo Live Biotherapeutic Products and Probiotics for the Skin Advanced NanoBiomed Research live biotherapeutic products probiotics skin formulation skin microbiome topical delivery |
| title | Live Biotherapeutic Products and Probiotics for the Skin |
| title_full | Live Biotherapeutic Products and Probiotics for the Skin |
| title_fullStr | Live Biotherapeutic Products and Probiotics for the Skin |
| title_full_unstemmed | Live Biotherapeutic Products and Probiotics for the Skin |
| title_short | Live Biotherapeutic Products and Probiotics for the Skin |
| title_sort | live biotherapeutic products and probiotics for the skin |
| topic | live biotherapeutic products probiotics skin formulation skin microbiome topical delivery |
| url | https://doi.org/10.1002/anbr.202100118 |
| work_keys_str_mv | AT avamvargason livebiotherapeuticproductsandprobioticsfortheskin AT aaroncanselmo livebiotherapeuticproductsandprobioticsfortheskin |